Grifols, S.A. (NASDAQ:GRFS – Get Free Report) saw a large decline in short interest during the month of July. As of July 31st, there was short interest totalling 7,570,000 shares, a decline of 6.5% from the July 15th total of 8,100,000 shares. Approximately 2.9% of the company’s shares are short sold. Based on an average trading volume of 1,490,000 shares, the short-interest ratio is currently 5.1 days.
Grifols Trading Up 0.1 %
GRFS opened at $7.19 on Wednesday. The business has a 50 day simple moving average of $7.39 and a two-hundred day simple moving average of $7.24. The firm has a market capitalization of $4.94 billion, a price-to-earnings ratio of 7.12 and a beta of 0.49. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.68 and a quick ratio of 1.29. Grifols has a one year low of $5.30 and a one year high of $12.15.
Grifols (NASDAQ:GRFS – Get Free Report) last released its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.21). The business had revenue of $1.96 billion for the quarter. Grifols had a net margin of 0.90% and a return on equity of 1.73%. Analysts predict that Grifols will post 0.79 EPS for the current year.
Institutional Inflows and Outflows
About Grifols
Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.
Featured Stories
- Five stocks we like better than Grifols
- What is a SEC Filing?
- Columbia Sportswear: A Turnaround Story That’s Gaining Ground
- What is the Euro STOXX 50 Index?
- Lowe’s Stock: Hold Now, Buy it When it Dips
- Options Trading – Understanding Strike Price
- ZIM Shipping Stock Soars as the Industry Shows a Bottoming Trend
Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.